Molecular mechanisms of paclitaxel and NM-3 on human gastric cancer in a severe combined immune deficiency mice orthotopic implantation model.
OBJECTIVE
To explore the molecular mechanisms of action of paclitaxel and NM-3 on human gastric cancer in severe combined immune deficiency (SCID) mice.


METHODS
Human gastric cancer cells SGC-7901 were implanted into SCID mice and mice were treated with paclitaxel and NM-3. The effects of paclitaxel and NM-3 on apoptosis of human gastric cancer cells were analyzed using flow cytometry, TUNEL assays, and DNA fragment analyses.


RESULTS
Apoptosis of SGC-7901 cells was successfully induced by paclitaxel, NM-3, and the combination of paclitaxel and NM-3 24 h after injection as shown by the presence of apoptotic hypodiploid peaks on the flow cytometer before G1-S and a characteristic apoptotic band pattern in the DNA electrophoresis. The apoptotic rate detected by TUNEL assay was found to be significantly higher in the paclitaxel/NM-3 compared to the control group (38.5% +/- 5.14% vs 13.2% +/- 1.75%, P < 0.01).


CONCLUSIONS
Paclitaxel in combination with NM-3 is able to induce apoptosis of the human gastric cancer cells in SCID mice effectively and synergistically.
Zhu
Jin-Shui
JS
Department of Gastroenterology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 200233, China. zhujs1803@hotmail.com
Song
Ming-Quan
MQ
Chen
Guo-Qiang
GQ
Li
Qin
Q
Sun
Qun
Q
Zhang
Qiang
Q
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000957:Antigens, Viral, Tumor / Q000187:drug effects / Q000235:genetics; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D049934:Isocoumarins / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D017239:Paclitaxel / Q000494:pharmacology*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014758:Viral Core Proteins / Q000187:drug effects / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
D000957:Antigens, Viral, Tumor; D000970:Antineoplastic Agents; D049934:Isocoumarins; D014758:Viral Core Proteins; C453300:isocoumarin NM-3; C055976:p27 antigen, Mouse mammary tumor virus; D017239:Paclitaxel
J Biol Chem. 2004 Apr 23;279(17):17283-8
15004027
Genes Dev. 1994 Jan;8(1):9-22
8288131
Oncogene. 2004 Jun 24;23(29):5105-9
15122318
Pancreas. 2004 Apr;28(3):353-8
15084985
World J Gastroenterol. 2003 Oct;9(10):2366-9
14562415
Hepatogastroenterology. 2004 Jan-Feb;51(55):68-75
15011833
Cancer Res. 2001 Aug 15;61(16):6163-9
11507068
Nature. 2004 Mar 11;428(6979):194-8
15014503
J Cell Physiol. 2000 Oct;185(1):1-20
10942515
Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1194-201
15037588
Oncology. 2002;63(4):398-404
12417796
Gynecol Oncol. 2002 Jul;86(1):19-23
12079294
Head Neck. 2003 Jan;25(1):44-9
12478543
Biochim Biophys Acta. 2004 May 3;1691(2-3):105-16
15110991
J Neurosurg. 2004 Sep;101(3):505-10
15352609
J Antibiot (Tokyo). 1990 Nov;43(11):1505-7
2272926
Glia. 2002 Feb;37(2):93-104
11754208
World J Gastroenterol. 2004 May 15;10(10):1425-30
15133847